Clearstead Advisors’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Clearstead Advisors’s Portfolio LKFT Stock Details LKFT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.99K	Buy	+67	New	+$1.92K	﹤0.01%	2481

Other funds holding LKFT

Gilead Sciences Foster City, California $1.46B AUM 71.23% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return

denkapparat Operations Berlin, Germany $379M AUM 28.36% 1-Year Est. Return

Crossmark Global Holdings Houston, Texas $7.69B AUM 31.68% 1-Year Est. Return

Monaco Asset Management Monaco $818M AUM 32.61% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return

MQS Management New York $171M AUM 3.86% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $77B AUM 19.24% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $134B AUM 35.21% 1-Year Est. Return

Clearstead Advisors's LKFT Position: Q3 2026 in Review

Clearstead Advisors opened a new position in Lakefront Biotherapeutics American Depositary Shares (LKFT) in Q3 2026: 67 shares worth $1.99K. The stake represents ﹤0.01% of the portfolio and ranks #2481 among its holdings.

40 funds tracked by Wall St. Rank hold LKFT as of Q3 2026.

Clearstead Advisors held 67 shares of Lakefront Biotherapeutics American Depositary Shares worth $1.99K as of Q3 2026.
Lakefront Biotherapeutics American Depositary Shares was a new Clearstead Advisors position in Q3 2026.
Lakefront Biotherapeutics American Depositary Shares made up ﹤0.01% of Clearstead Advisors's portfolio in Q3 2026, its #2481 holding.
40 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q3 2026.

Based on Clearstead Advisors's 13F filing for Q3 2026, filed 6 Nov 2026.